Heart Failure

Patients hospitalized with COVID-19 had higher rates of readmission or death 10 days after discharge compared with those with pneumonia or heart failure, according to research published in JAMA.

At 6 months, quality of life in patients with permanent atrial fibrillation and symptomatic HF treated with digoxin was not significantly different vs. those treated with bisoprolol, researchers reported.

Preventive HF strategies must be broadened to target patients with diabetes, according to study findings published in JAMA Cardiology.

Abbott announced the FDA approved updated labeling for its implantable heart pump for use in pediatric patients with advanced refractory left ventricular HF.

A randomized phase 3 trial designed to evaluate rexlemestrocel-L for patients with advanced chronic heart failure failed to achieve its primary endpoint, according to topline data released by the agent’s manufacturer.

High-dose vs. low-dose flu vaccine effect on cardiopulmonary events in high-risk patients.

Omecamtiv mecarbil (Amgen/Cytokinetics/Servier) for reduction of HF events and death in HF with reduced ejection fraction.

The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 12-1 that an expanded indication is warranted for sacubitril/valsartan, which could allow it as a treatment for certain patients with HF with preserved ejection fraction.

Adults with healthy sleep patterns had lower risk for HF compared with adults with unhealthy sleep patterns, according to findings published in Circulation.

Among patients with HF with preserved ejection fraction, those with ischemic heart disease had increased risk for major adverse renal and/or cardiac events, according to study findings published in The American Journal of Cardiology.